Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: A critical approach

Journal of the American Society of Hypertension

Volumn 4, Issue 3, 2010, Pages 116-127

  Hogas, Simona M ^a   Voroneanu, Luminita ^a   Serban, Dragomir N ^b   Segall, Liviu ^a   Hogas, Mihai M ^b   Serban, Ionela Lacramioara ^b   Covic, Adrian ^a  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

arterial stiffness; cardiovascular risk factors; inflammation; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ARGININE; ATORVASTATIN; BIOLOGICAL MARKER; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LEPTIN; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; OMEGA 3 FATTY ACID; OSTEOPROTEGERIN; PAPAVERINE; PENTRAXIN 3; PRAVASTATIN; PYRIDOXINE; ROSUVASTATIN; SIMVASTATIN; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; APPLANATION TONOMETRY; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM; FOREARM BLOOD FLOW; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; INVASIVE PROCEDURE; IONTOPHORESIS; KIDNEY TRANSPLANTATION; LASER DOPPLER FLOWMETRY; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; NONHUMAN; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; RISK FACTOR; SKIN BLOOD FLOW; STEM CELL; TONOMETRY; UREMIA; VASODILATATION; VASOMOTOR REFLEX; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; VASODILATION;

EID: 77954753231     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.03.008     Document Type: Review

References (120)

1. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
2. P. Gusbeth-Tatomir, and A. Covic Causes and consequences of increased arterial stiffness in chronic kidney disease patients Kidney Blood Press Res 30 2007 97 107
3. D.E. Weiner, S. Tabatabai, H. Tighiouart, E. Elsayed, N. Bansal, and J. Griffith Cardiovascular outcomes and all-cause mortality. Exploring the interaction between CKD and cardiovascular disease Am J Kidney Dis 48 2006 392 401
4. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia. Oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538
5. J. Zimmermann, S. Herrlinger, A. Pruy, T. Metzger, and C. Wanner Inflammation enhances cardiovascular risk and mortality in hemodialysis patients Kidney Int 55 1999 648 658
6. R. Vlaicu, H.G. Rus, F. Niculescu, and A. Cristea Immunoglobulins and complement components in human aortic atherosclerotic intima Atherosclerosis 55 1985 35 50 (Pubitemid 15064937)
7. Y.X. Zhang, W.J. Cliff, G.I. Schoefl, and G. Higgins Coronary C-reactive protein distribution: its relation to development of atherosclerosis Atherosclerosis 145 1999 375 379
8. C. Zoccalli Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension J Am Soc Nephrol 17 2006 S61 S63
9. S. Verma, C.H. Wang, S.H. Li, A.S. Dumont, P.W. Fedak, and M.V. Badiwala A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2002 913 919
10. S.J. Cleland, N. Sattar, J.R. Petrie, N.G. Forouhi, H.L. Elliott, and J.M. Connell Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease Clin Sci 98 2000 531 535
11. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Lancet 339 1992 572 575
12. R. Wever, P. Boer, M. Hijmering, E. Stroes, M. Verhaar, and J. Kastelein Nitric oxide production is reduced in patients with chronic renal failure Arterioscler Thromb Vasc Biol 19 1999 1168 1172
13. C. Zoccali, F. Mallamaci, and G. Tripepi Inflammation and atherosclerosis in end-stage renal disease Blood Purif 21 2003 29 36
14. P.S. Modlinger, C.S. Wilcox, and S. Aslam Nitric oxide, oxidative stress, and progression of chronic renal failure Semin Nephrol 24 2004 354 365
15. C. McIntyre, J. Burton, N. Selby, L. Leccisotti, S. Korsheed, and C. Baker Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow Clin J Am Soc Nephrol 3 2008 19 26
16. T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Münzel Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease Circulation 104 2001 2673 2678
17. K. Caglar, M.I. Yilmaz, M. Saglam, E. Cakir, S. Kilic, and A. Sonmez Serum fetuin-A concentration and endothelial dysfunction in chronic kidney disease Nephron Clin Pract 108 2008 233 240
18. E. Schiffrin, M. Lipman, and J. Mann Chronic kidney disease: effects on the cardiovascular system Circulation 116 2007 85 97
19. D. Brancaccio, M. Gallieni, S. Pasho, G. Fallabrino, L. Olivi, and E. Volpi Pathogenesis and treatment of vascular calcification in CKD G Ital Nefrol 26 2009 S20 S27
20. A. Covic, P. Gusbeth-Tatomir, and D.J. Goldsmith Vascular calcification - a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity Semin Dial 20 2007 158 169
21. G.M. London Bone-vascular axis in chronic kidney disease: a reality? Clin J Am Soc Nephrol 4 2009 254 257
22. I.B. Wilkinson, A. Qasem, C.M. McEniery, D.J. Webb, A.P. Avolio, and J.R. Cockcroft Nitric oxide regulates local arterial distensibility in vivo Circulation 105 2002 213 217
23. M. Schmitt, A. Avolio, A. Qasem, C.M. McEniery, M. Butlin, and I.B. Wilkinson Basal NO locally modulates human iliac artery function in vivo Hypertension 46 2005 227 231
24. T.J. Vuurmans, P. Boer, and H.A. Koomans Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans Hypertension 41 2003 1253 1258
25. A.P. Guerin, G.M. London, S.J. Marchais, and F. Metivier Arterial stiffening and vascular calcifications in end-stage renal disease Nephrol Dial Transplant 15 2000 1014 1021
26. A.A. Haydar, A. Covic, H. Colhoun, M. Rubens, and D.J.A. Goldsmith Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients Kidney Int 65 2004 1790 1794
27. S.M. Moe, and N.X. Chen Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol 19 2008 213 216
28. J. Zhang, M. Fu, D. Myles, X. Zhu, J. Du, and X. Cao PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways FEBS Lett 521 2002 180 184
29. M.E. Suliman, E. Garcia-Lopez, B. Anderstam, B. Lindholm, and P. Stenvinkel Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease Adv Clin Chem 46 2008 217 262
30. A. Haydar, A. Covic, H. Colhoun, M. Rubens, and D. Goldsmith Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients Kidney Int 65 2004 1790 1794
31. N. van Popele, D. Grobbee, M. Bots, R. Asmar, J. Topouchian, and R. Reneman Association between arterial stiffness and atherosclerosis: the Rotterdam Study Stroke 32 2001 454 460 (Pubitemid 32155234)
32. M. Kanbay, B. Afsar, P. Gusbeth-Tatomir, and A. Covic Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol 2009 10.1007/s11255-009-9675-1
33. S. Hanada, R. Ando, S. Naito, N. Kobayashi, M. Wakabayashi, and T. Hata Assessment and significance of abdominal aortic calcification in chronic kidney disease Nephrol Dial Transplant 2010 10.1093/ndt/gfp728
34. M. Sharon, X.C. Neal, F.S. Mark, R.M. Sinders, D. Duan, and X. Chen A rat model of chronic kidney disease-mineral bone disorder (CKD-MBD) and the effect of dietary protein source Kidney Int 75 2009 176 184
35. J. Pelisek, A. Assadian, O. Sarkar, H.H. Eckstein, and H. Frank Carotid plaque composition in chronic kidney disease: a retrospective analysis of patients undergoing carotid endarterectomy Eur J Vasc Endovasc Surg 2009 10.1016/j.ejvs.2009.09.024
36. G. London, S. Marchais, A. Guerin, F. Metivier, and H. Adda Arterial structure and function in end-stage renal disease Nephrol Dial Transplant 17 2002 1713 1724 (Pubitemid 35174279)
37. M.E. Widlansky, N. Gokce, J.F. Keaney, and J.A. Vita The clinical implication of endothelial dysfunction J Am Coll Cardiol 42 2003 1149 1160
38. D. Tousoulis, C. Antoniades, and C. Stefanadis Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques Heart 91 2005 553 558
39. A.O. Ozdemir, S. Gulec, N. Uslu, C.T. Kaya, C. Ozdol, and S. Turhan The relation between endothelial dependent flow mediated dilation of the brachial artery and coronary collateral development - a cross sectional study Cardiovasc Ultrasound 15 2009 7 25
40. D.P. Casey, W.W. Nichols, C.R. Conti, and R.W. Braith Relationship between endogenous concentrations of vasoactive substances and measures of peripheral vasodilator function in patients with coronary artery disease Clin Exp Pharmacol Physiol 37 2009 24 28
41. T. Nakamura, J.E. Obata, M. Hirano, Y. Kitta, K. Sano, and T. Kobayashi Endothelial vasomotor dysfunction in the sbrachial artery predicts the short-term development of early stage renal dysfunction in patients with coronary artery disease Int J Cardiol 2009 10.1016/j.ijcard.2009.10.054
42. R.J. Woodman, D.A. Playford, G.F. Watts, C. Cheetham, C. Reed, and R.R. Taylor Improved analysis of brachial artery ultrasound images using a novel edge-detection software system J Appl Physiol 91 2001 929 937
43. H. Miyazaki, H. Matsuoka, H. Itabe, M. Usui, S. Ueda, and S. Okuda Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer Circulation 101 2000 1002 1006
44. G.M. London, J. Blacher, B. Pannier, A.P. Guerin, S.J. Marchais, and M.E. Safar Arterial wave reflections and survival in end-stage renal failure Hypertension 38 2001 434 448
45. B. Pannier, A.P. Guerin, S.J. Marchais, M.E. Safar, and G.M. London Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients Hypertension 45 2005 592 596
46. C.S. Hayward, M. Kraidly, C.M. Webb, and P. Collins Assessment of endothelial function using peripheral waveform analysis: a clinical application J Am Coll Cardiol 40 2002 521 528
47. A.M.A. Schabauer, and T.W. Rooke Cutaneous laser Doppler flowmetry: applications and findings Mayo Clin Proc 69 1994 564 574
48. F. Jung, C. Mrowietz, and C. Labarrere Primary cutaneous microangiopathy in heart recipients Microvasc Res 62 2001 154 163
49. A. Kruger, J. Stewart, R. Sahityani, E. O'Riordan, C. Thompson, and S. Adler Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk Kidney Int 70 2006 157 164
50. Y.N. Kalia, A. Naik, J. Garrison, and R.H. Guy Iontophoretic drug delivery Adv Drug Deliv Rev 56 2004 619 658
51. P.L. Ludmer, A.P. Selwyn, T.L. Shook, R.R. Wayne, G.H. Mudge, and R.W. Alexander Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries N Engl J Med 315 1986 1046 1051
52. J.A. Vita, C.B. Treasure, E.G. Nabel, J.M. McLenachan, R.D. Fish, and A.C. Yeung Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease Circulation 81 1990 491 497
53. J.L. Cracowski, C.T. Minson, M. Salvat-Melis, and J.R. Halliwill Methodological issues in the assessment of skin microvascular endothelial function in humans Trends Pharmacol Sci 27 2006 503 508
54. J. Turner, J.J.F. Belch, and F. Khan Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis Trends Cardiovasc Med 18 2008 109 116
55. J.A. Vita, and J.F. Keaney Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 106 2002 640 642
56. J.A. Suwadi, S. Hamasaki, S.T. Higano, R.A. Nishimura, D.R. Holmes Jr., and A. Lerman Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction Circulation 101 2000 948 954
57. V. Schächinger, M.B. Britten, and A.M. Zeiher Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 101 2000 1899 1906
58. J.P. Halcox, W.H. Schenke, G. Zalos, R. Mincemoyer, A. Prasad, and M.A. Waclawiw Prognostic value of coronary vascular endothelial dysfunction Circulation 106 2002 653 658
59. P.V. Targonski, P.O. Bonetti, G.M. Pumper, S.T. Higano, D.R. Holmes Jr., and A. Lerman Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events Circulation 107 2003 2805 2809
60. F. Perticone, R. Ceravolo, A. Pujia, G. Ventura, S. Iacopino, and A. Scozzafava Prognostic significance of endothelial dysfunction in hypertensive patients Circulation 104 2001 191 196
61. J.T. Kielstein, R.H. Boger, S.M. Bode-Boger, J.C. Frolich, H. Haller, and E. Ritz Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease J Am Soc Nephrol 13 2002 170 176
62. C. Zoccali, F.A. Benedetto, R. Maas, F. Mallamaci, G. Tripepi, and L.S. Malatino Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease J Am Soc Nephrol 13 2002 490 496
63. J.M. Young, N. Terrin, X. Wang, T. Greene, G.J. Beck, and J.W. Kusek Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease Clin J Am Soc Nephrol 4 2009 1115 1120
64. C. Zoccali, S.M. Bode-Böger, F. Mallamaci, F.A. Benedetto, G. Tripepi, and L.S. Malatino Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study Lancet 358 2001 2113 2117
65. R.H. Boger, and C. Zoccali ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease Atheroscler Suppl 4 2003 23 28
66. J. Zsuga, J. Torok, M.T. Magyar, A. Valikovics, R. Gesztelyi, and S. Kéki Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis Cerebrovasc Dis 23 2007 388 394
67. K.B. Holven, T.S. Haugstad, T. Holm, P. Aukrust, L. Ose, and M.S. Nenseter Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects Br J Nutr 89 2003 359 363
68. S. Ziegler, F. Mittermayer, C. Plank, E. Minar, M. Wolzt, and G.H. Schernthaner Homocysteine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease J Clin Endocrinol Metab 90 2005 2175 2178
69. T.M. Lu, Y.A. Ding, H.B. Leu, W.H. Yin, W.H. Sheu, and K.M. Chu Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia Am J Cardiol 94 2004 157 161
70. P.W. Nanayakkara, J.C. Kiefte-de Jong, P.M. ter Wee, C.D. Stehouwer, F.J. van Ittersum, and M.R. Olthof Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD Am J Kidney Dis 53 2009 41 50
71. R. Maas Pharmacotherapies and their influence on asymmetric dimethylarginine (ADMA) Vasc Med 10 2007 S49 S57
72. J. Kielstein, F. Donnerstag, S. Gasper, J. Menne, A. Kielstein, and J. Martens-Lobenhoffer ADMA increases arterial stiffness and decreases cerebral blood flow in humans Stroke 37 2006 2024 2029
73. L.L. Horstman, W. Jy, J.J. Jimenez, and Y.S. Ahn Endothelial microparticles as markers of endothelial dysfunction Front Biosci 9 2004 1118 1135
74. I. Dursun, H.M. Poyrazoglu, Z. Gunduz, H. Ulger, A. Yykylmaz, and R. Dusunsel The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease Nephrol Dial Transplant 24 2009 2511 2518
75. N. Amabile, A.P. Guerin, A. Leroyer, Z. Mallat, C. Nguyen, and J. Boddaert Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure J Am Soc Nephrol 16 2005 3381 3388
76. C.M. Boulanger, A. Scoazec, T. Ebrahimian, P. Henry, E. Mathieu, and A. Tedgui Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction Circulation 104 2001 2649 2652
77. W. Jy, L.L. Horstman, J.J. Jimenez, Y.S. Ahn, E. Biro, and R. Nieuwland Measuring circulating cell-derived microparticles J Thromb Haemost 2 2004 1842 1843
78. A. Mantovani, C. Garlanda, B. Bottazzi, G. Peri, A. Doni, and Y. Martinez de la Torre The long pentraxin PTX3 in vascular pathology Vascul Pharmacol 45 2006 326 330
79. M. Tong, J.J. Carrero, A.R. Qureshi, B. Anderstam, O. Heimbürger, and P. Bárány Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality Clin J Am Soc Nephrol 2 2007 889 897
80. M. Boehme, F. Kaehne, A. Kuehne, W. Bernhardt, M. Schroder, and W. Pommer Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease Nephrol Dial Transplant 22 2007 2224 2229
81. M.E. Suliman, M.I. Yilmaz, J.J. Carrero, A.R. Qureshi, M. Saglam, and O.M. Ipcioglu Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease Clin J Am Soc Nephrol 3 2008 976 985
82. M.Y. Yilmaz, J. Axelsson, A. Sonmez, J.J. Carrero, M. Saglam, and T. Eyileten Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria Clin J Am Soc Nephrol 2009 10.2215/CJN.04330808
83. M.A. Aminzadeh, M.V. Pahl, C.H. Barton, N.S. Doctor, and N.D. Vaziri Human uraemic plasma stimulates release of leptin and uptake of tumour necrosis factor-α in visceral adipocytes Nephrol Dial Transplant 24 2009 3626 3631
84. H. Kastarinen, Y.A. Kesäniemi, and O. Ukkola Leptin and lipid metabolism in chronic kidney failure Scand J Clin Lab Invest 69 2009 401 408
85. K.M. Naseem The role of nitric oxide in cardiovascular diseases Mol Aspects Med 26 2005 33 65
86. A. Scholze, D. Rattensperger, W. Zidek, and M. Tepel Low serum leptin predicts mortality in patients with chronic kidney disease stage 5 Obesity 15 2007 1617 1622
87. M.I. Yilmaz, M. Saglam, J.J. Carrero, A.R. Qureshi, K. Caglar, and T. Eyileten Serum visfatin concentration and endothelial dysfunction in chronic kidney disease Nephrol Dial Transplant 23 2008 959 965 (Pubitemid 351767576)
88. J. Axelsson, A. Witasp, J.J. Carrero, A.R. Qureshi, M.E. Suliman, and O. Heimbürger Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD Am J Kidney Dis 49 2007 237 244
89. M. Zhong, H.W. Tan, H.P. Gong, S.F. Wang, Y. Zhang, and W. Zhang Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis Clin Endocrinol 69 2008 878 884
90. K.D. Nusken, M. Petrasch, M. Rauh, W. Stohr, E. Nusken, and H. Schneider Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol Nephrol Dial Transplant 24 2009 2832 2838
91. K. Takebayashi, M. Suetsugu, and S. Wakabayashi Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus Metabolism 56 2007 451 458
92. M.K. Sigrist, A. Levin, L. Er, and C.W. McIntyre Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification Nephrol Dial Transplant 24 2009 3157 3162
93. L.C. Hofbauer, C. Shui, B.L. Riggs, C.R. Dunstan, T.C. Spelsberg, and T. O'Brien Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells Biochem Biophys Res Commun 280 2001 334 339
94. J.Y. Shin, Y.G. Shin, and C.H. Chung Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes Diabetes Care 29 2006 1664 1666
95. M. Morena, N. Terrier, I. Jaussent, H. Leray-Moragues, L. Chalabi, and J.P. Rivory Plasma osteoprotegerin is associated with mortality in hemodialysis patients J Am Soc Nephrol 17 2006 262 270
96. G. Speer, B. Fekete, T.E.H. Othmane, T. Szabo, J. Egresits, and E. Fodor Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients Nephrol Dial Transplant 23 2008 3256 3262
97. P. Collin-Osdoby Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin Circ Res 95 2004 1046 1057
98. B. Akinci, T. Demir, A. Celtik, M. Baris, S. Yener, and M.A. Ozcan Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes Diabetes Res Clin Pract 82 2008 172 178
99. X. Guang-da, S. Hui-ling, and H. Jie Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia Clin Endocrinol (Oxf) 69 2008 799 803
100. P.E. Szmitko, P.W. Fedak, R.D. Weisel, D.J. Stewart, M.J. Kutryk, and S. Verma Endothelial progenitor cells: new hope for a broken heart Circulation 107 2003 3093 3100
101. C. Heiss, S. Keymel, U. Niesler, J. Ziemann, M. Kelm, and C. Kalka Impaired progenitor cell activity in age-related endothelial dysfunction J Am Coll Cardiol 45 2005 1441 1448
102. M. Vasa, S. Fichtlscherer, K. Adler, A. Aicher, H. Martin, and A.M. Zeiher Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease Circulation 103 2001 2885 2890
103. C. Heeschen, A. Aicher, R. Lehmann, S. Fichtlscherer, M. Vasa, and C. Urbich Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization Blood 102 2003 1340 1346
104. H. Ueno, H. Koyama, S. Fukumoto, S. Tanaka, T. Shoji, and T. Shoji Dialysis modality is independently associated with circulating endothelial progenitor cells in end-stage renal diseases patients Nephrol Dial Transplant 2009 10.1093/ndt/gfp358
105. N. Jourde-Chiche, L. Dou, F. Sabatier, R. Calaf, C. Cerini, and S. Robert Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients J Thromb Haemost 7 2009 1576 1584
106. C. Dogra, H. Changotra, N. Wedhas, X. Qin, J.E. Wergedal, and A. Kumar TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine FASEB J 21 2007 1857 1869
107. J.J. Carrero, A. Ortiz, A.R. Qureshi, J.L. Martín-Ventura, P. Bárány, and O. Heimbürger Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients Clin J Am Soc Nephrol 4 2009 110 118
108. J.A. Winkles The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting Nat Rev Drug Discov 7 2008 411 425
109. M.I. Yilmaz, J.J. Carrero, A. Ortiz, J.L. Martín-Ventura, A. Sonmez, and M. Saglam Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease Clin J Am Soc Nephrol 4 2009 1716 1723
110. N. Harada, M. Nakayama, H. Nakano, Y. Fukuchi, H. Yagita, and K. Okumura Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells Biochem Biophys Res Commun 299 2002 488 493
111. P.J. Donohue, C.M. Richards, S.A. Brown, H.N. Hanscom, J. Buschman, and S. Thangada TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity Arterioscler Thromb Vasc Biol 23 2003 594 600
112. J. Passauer, E. Bussemaker, G. Lassig, and P. Gross Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease Transplantation 75 2003 1907 1910
113. E.L. Schiffrin, and R.M. Touyz Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade J Am Coll Cardiol 42 2003 911 913
114. G.K. Dogra, G.F. Watts, S. Herrmann, M.A. Thomas, and A.B. Irish Statin therapy improves brachial artery endothelial function in nephrotic syndrome Kidney Int 62 2002 550 557
115. J.L. Mehta, D.Y. Li, H.J. Chen, J. Joseph, and F. Romeo Inhibition of LOX-1 by statins may relate to upregulation of eNOS Biochem Biophys Res Commun 289 2001 857 861
116. L.S. Rallidis, G. Paschos, G.K. Liakos, A.H. Velissaridou, G. Anastasiadis, and A. Zampelas Dietary α-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients Atherosclerosis 167 2003 237 242
117. J. Goodfellow, M.F. Bellamy, M.W. Ramsey, J.H.C. Jones, and M.J. Lewis Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia J Am Coll Cardiol 35 2000 265 270
118. C. Zoccali, F. Mallamaci, R. Maas, F.A. Benedetto, G. Tripepi, and L.S. Malatino Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients Kidney Int 62 2002 339 345
119. M. Hausberg, K. Kisters, M. Kosch, and M. Barenbrock Alterations of the arterial vessel wall in renal failure Med Klin 95 2000 279 285 (Pubitemid 30331374)
120. D. Goldsmith, R. MacGinley, A. Smith, and A. Covic How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 17 2002 965 969